The investor webcast presentation agenda to assessment the IDE397 scientific information replace of the Section 2 growth dose leads to MTAP-deletion urothelial and NSCLC sufferers would be the following:
- Market introduction: U.S. annual incidence in MTAP-deletion strong tumors
- IDE397 preclinical abstract in MTAP-deletion
- Affected person baseline traits
- Pharmacokinetics and pharmacodynamics
- Antagonistic occasion profile
- Scientific efficacy in 18 evaluable MTAP-deletion urothelial and NSCLC sufferers by RECIST 1.1
- General Response Charge (%ORR) and Illness Management Charge (%DCR) evaluation
- Swimlane plot
- ctDNA molecular response evaluation
- Case reviews and CT-scan photographs
The IDEAYA audio system will embody Yujiro S. Hata, Chief Government Officer, Darrin Beaupre, M.D., Ph.D., Chief Medical Officer, and Michael White, Ph.D., Chief Scientific Officer. The hyperlink to the investor webcast can be out there on the Investor Relations Occasions part of the Firm’s web site at: https://ir.ideayabio.com/occasions. Registration is accessible at https://ir.ideayabio.com/occasions or https://lifescievents.com/occasion/ideaya-2/ upfront of the occasion.
IDEAYA’s IDE397 investor webcast presentation, in addition to an up to date company presentation, which is able to incorporate the up to date IDE397 scientific information, can be out there on the corporate’s web site, at its Investor Relations portal (https://ir.ideayabio.com/) at roughly 8:00 am ET on Monday, July 8, 2024.
There’s an ongoing Section 2 growth of IDE397 monotherapy in MTAP-deletion strong tumors (NCT04794699), and an Amgen-sponsored Section 1/2 trial of IDE397 and Amgen’s investigational MTA-cooperative protein arginine methytranferase 5 inhibitor AMG 193 mixture in MTAP-deletion NSCLC (NCT05975073) for which the businesses intend to develop a joint publication technique in 2024. As well as, IDEAYA has initiated enrollment in a Section 1 scientific trial evaluating the protection, tolerability, pharmacokinetics, pharmacodynamics and efficacy of IDE397 together with Gilead’s Trop-2 directed anti-body conjugate Trodelvy (NCT04794699). IDEAYA can be advancing a number of preclinical stage MTAP-deletion applications to allow wholly-owned mixtures with IDE397, together with a program focusing on a improvement candidate nomination within the second half of 2024.
About IDEAYA Biosciences
IDEAYA is a precision drugs oncology firm dedicated to the invention and improvement of focused therapeutics for affected person populations chosen utilizing molecular diagnostics. IDEAYA’s method integrates capabilities in figuring out and validating translational biomarkers with drug discovery to pick affected person populations most probably to learn from its focused therapies. IDEAYA is making use of its analysis and drug discovery capabilities to artificial lethality – which represents an rising class of precision drugs targets.
Ahead-Trying Statements
This press launch accommodates forward-looking statements, together with, however not restricted to, statements associated to (i) the timing and content material of the IDE397 scientific information replace press launch, investor webcast and investor displays, (ii) the timing for the event of a joint Amgen/IDEAYA publication technique for the Section 1/2 IDE397 and AMG 193 mixture, (iii) the timing of preclinical stage MTAP-deletion applications together with IDE397 and (iv) nomination of an IDE397 mixture improvement candidate within the second half of 2024. IDEAYA undertakes no obligation to replace or revise any forward-looking statements. Such forward-looking statements contain substantial dangers and uncertainties. For an additional description of the dangers and uncertainties that might trigger precise occasions and outcomes to vary from these expressed in these forward-looking statements, in addition to dangers referring to the enterprise of IDEAYA basically, see IDEAYA’s Annual Report on Kind 10-Ok filed on February 20, 2024, Quarterly Report on Kind 10-Q filed on Could 7, 2024 and any extra present and periodic reviews filed with the
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
SVP, Head of Finance and Investor Relations
investor@ideayabio.com
View authentic content material to obtain multimedia:https://www.prnewswire.com/news-releases/ideaya-announces-investor-webcast-to-report-clinical-data-update-for-ide397-phase-2-monotherapy-expansion-dose-in-mtap-deletion-urothelial-and-lung-cancer-on-monday-july-8-2024-302190198.html
SOURCE IDEAYA Biosciences, Inc.
